Fig. 7

Positivity for CLEC10A ligands is an independent prognostic marker in breast cancer and is associated with favorable outcome. a Applying protein histochemistry, 146 paraffin-embedded human breast cancer samples were stained by recombinant CLEC10A. Based on staining intensity and shown by two representative examples, tumors were assigned to the following two groups: no (A, B) to weak staining (C, D) and moderate (E, F) to strong staining (G, H). Two representative cases are shown for each of the different staining categories. DAB was used for detection and sections were counterstained by hematoxylin. (Scale bar: 100 μm). b Log-rank Kaplan Meier analysis of disease-free survival and overall survival of the 146 breast cancer patients. For CLEC10A positive tumors, disease free survival was increased on average by approximately 13 month from 62,1 months (95% confidence interval: 55,2–68,9 months) to 75,8 months (95% ci: 67,5 - 84,2). Overall survival increased by approximately 19 months from 67,5 months (95% ci: 60,1–74,9 months) to 86,7 months (95% ci: 78,6 - 94,8). c Hazard ratios of CLEC10A staining and other clinico-pathological parameters for overall survival in breast cancer determined by Cox regression (proportional hazards model); levels of significance are given on the right (ns = not significant). d CLEC10A Far Western Blot analysis of input (i), flow through (f) and eluate fractions (E1-E3) after CLEC10A pull down using two different breast cancer tumors positive for CLEC10A. e Silver staining of protein fractions eluted by EDTA after CLEC10A pull down. Gel slices marked by colored boxes were excised and analyzed by mass spectrometry